Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
:ALKS
Holding ALKS?
Track your performance easily
ALKS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.90 - $32.88
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.55M
Market Cap
$4.61B
Enterprise Value$4.13B
Total Cash (Recent Filing)$497.23M
Total Debt (Recent Filing)$280.67M
Price to Earnings (P/E)14.8
Beta0.75
Next Earnings
Feb 13, 2025EPS Estimate
0.74Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)1.96
Shares Outstanding161,802,500
10 Day Avg. Volume1,388,898
30 Day Avg. Volume1,546,021
Standard Deviation0.10
R-Squared0.05
Alpha0.00607
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.12
Price to Cash Flow (P/CF)14.40
P/FCF Ratio16.00
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.75
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda8.09
Forecast
1Y Price Target
$35.00Price Target Upside20.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Alkermes News
PremiumCompany Announcements
Alkermes Advances Orexin Program with ALKS 2680 Candidate
PremiumCompany Announcements
Alkermes Prepares for New Flexibility Post Credit Termination
PremiumCompany Announcements
Alkermes Aims for Growth with Neuroscience Focus
Bulls Say, Bears Say
Bulls Say
Market OpportunityManagement believes the market potential for narcolepsy is large, with narcolepsy type I alone potentially being a multi-billion opportunity for the orexin-2 receptor agonist class.
Product PotentialALKS-2680 is expected to gain greater attention due to its potential to be disruptive in the $10B branded narcolepsy and idiopathic hypersomnia markets.
Stock PerformanceAnalyst reiterates an Outperform rating and raises the price target from $35 to $40, indicating confidence in the stock's performance.
Bears Say
Financial OutlookManagement expects EBITDA to decrease, with an expected negative impact in royalty and manufacturing revenue.
Revenue DeclineManagement flagged expected declines in the manufacturing and royalty segment due to expiration of the royalty for Invega Sustenna.
Sales PerformanceSales for certain core products like Lybalvi and Aristada could be light, which might affect short-term performance.
---
Ownership Overview
1.49% Insiders
34.10% Mutual Funds
0.30% Other Institutional Investors
30.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $22.90 and its highest was $32.88 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $4.61B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Oct 24, 2024. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.7 by $0.02.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc pays a Notavailable dividend of $1.639 which represents an annual dividend yield of N/A. See more information on Alkermes plc dividends here
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is 0.74.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 161,802,500 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $0.72 in its last earnings report, beating expectations of $0.7. Following the earnings report the stock price went down -3.591%.
Which hedge fund is a major shareholder of Alkermes plc?
Among the largest hedge funds holding Alkermes plc’s share is Baker Bros Advisors LP. It holds Alkermes plc’s shares valued at 117M.
---
Alkermes Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (20.48% Upside)
$35.00 (20.48% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 262.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.16%
12-Months-Change
Fundamentals
Return on Equity
29.23%
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented strong growth metrics in the proprietary product portfolio, especially VIVITROL and LYBALVI, and a solid financial position. However, there are challenges in the schizophrenia market and expected declines in royalty and manufacturing revenues, impacting future profitability.Read More>---
ALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
---
ALKS Stock 12 Month Forecast
Average Price Target
$35.00
▲(20.48% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
SAGE Therapeutics
―
Neurocrine
―
Intra-Cellular Therapies
―
Vertex Pharmaceuticals
―
BioMarin Pharmaceutical
―
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+5.71%
reiterated a buy rating 3 months ago
Copying Akash Tewari's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +5.71% per trade.
---